NASDAQ:NGNE
Neurogene Inc.
Neurogene Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$78.4M, and the diluted share count rose 21.4%.Summary generated from Neurogene Inc.'s SEC filings. Latest annual report filed Mar 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−31.4%
Debt / equityn/a
Free cash flow−$78.4M
FCF marginn/a
Share count change+21.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 1 | 0 |
| Operating income | −61 | −57 | −56 | −83 | −103 |
| Net income | −61 | −55 | −36 | −75 | −90 |
| Free cash flow | −51 | −55 | −52 | −71 | −78 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jul 7, 2026 - 8-KEntry into a material agreement
Jul 2, 2026 - 8-KRegulation FD disclosure
Jun 29, 2026 - 8-KRegulation FD disclosure
Jun 8, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026